Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Efficacy and Safety of Yishen Daluo Yin Granule for Relapsing-Remitting Multiple Sclerosis

The aim of this study is to evaluate the efficacy and safety of YSDLY granule in patients with RRMS. This will be a multi-center, randomized, double-blind, placebo-controlled study.

Participants needed: 152
Trial details
Age: 18-55Biological sex: AllType: InterventionalSponsor: Ying GaoUpdated: Feb 4, 2026
Eligibility criteria

Participants aged 18 to 55 when signing the informed consent, with no gender res... [+6]

According to the 2017 McDonald's guidelines and the 2023 version of the Chinese... [+20]

Read more
Status: Not yet recruiting

Effectiveness of the Combination Strategy of Disease-Modifying Therapy and the Yishen Daluo Yin Modified Formula for Multiple Sclerosis

This study was designed to investigate the effectiveness of a combined strategy utilizing disease-modifying therapy and the modified Yishen Daluo Yin formula for relapsing-remitting multiple sclerosis (RRMS) through a prospective, multicenter, observational comparative study.

Participants needed: 328
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Ying GaoUpdated: Jun 26, 2025
Eligibility criteria

Participants who are over 18 years old at the time of signing the informed conse... [+5]

According to the 2017 McDonald's guidelines and the 2023 version of the Chinese... [+6]

Read more
Status: Not yet recruiting

Effectiveness of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke

The primary purpose of this study is to investigate the effectiveness of Ginkgo Diterpene Lactone Meglumine (GDLM) for patients with acute ischemic stroke (AIS) in real-world settings.

Participants needed: 4,460
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Ying GaoUpdated: Mar 6, 2025Locations: 10
Eligibility criteria

aged ≥18 years, regardless of gender [+2]

mRS score of 2 or more prior to onset [+4]

Read more